Plain-English translation of NCT07299500 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Strasbourg University Hospital are studying patients who developed toxoplasmosis—a serious infection caused by a parasite—while having a weakened immune system from sources other than HIV. By reviewing medical records from 2010 to 2023, doctors want to understand how this infection affects different groups of immunocompromised patients and learn the best ways to diagnose, treat, and prevent it.
Toxoplasmosis in HIV-positive patients is well understood with clear treatment guidelines, but very little is known about how to manage this infection in other immunocompromised patients, such as those who have had organ transplants, received stem cell transplants, or are taking immune-suppressing medications. This study aims to fill that gap and create better care standards.
You likely qualify if…
You likely don't qualify if…
As a participant, you would not need to attend visits or take any new medications. Instead, researchers would review your existing medical records from Strasbourg University Hospital to gather information about your toxoplasmosis diagnosis, how it was treated, and your outcomes. The study is retrospective, meaning it only looks back at past care you have already received.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
France
Sponsor
University Hospital, Strasbourg, France
Enrollment target
~30 participants
Started
February 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mathilde HERBER, MD
University Hospital, Strasbourg, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.